Search

Your search keyword '"Antibodies, Monoclonal blood"' showing total 1,600 results

Search Constraints

Start Over You searched for: Descriptor "Antibodies, Monoclonal blood" Remove constraint Descriptor: "Antibodies, Monoclonal blood"
1,600 results on '"Antibodies, Monoclonal blood"'

Search Results

1. Gábor Transform-Based Antibody Quantitation in Serum: An Interlaboratory Liquid Chromatography/High-Resolution Mass Spectrometry Investigation.

3. Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody-drug conjugate.

4. Generic Enrichment Method for Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Assay for Quantitative Measurement of Biological Therapeutics in Serum.

5. HPLC-MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serum.

6. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a recombinant humanized anti-IL-4Rα monoclonal antibody CM310 in serum and its application to pharmacokinetic study in Sprague-Dawley Rats.

7. High-throughput, low-cost quantification of 11 therapeutic antibodies using caprylic acid precipitation and LC-MS/MS.

8. Quantitative assessment of daratumumab in serum via intact light chain measurement using liquid chromatography-high resolution mass spectrometry: a method suitable for therapeutic drug monitoring.

9. Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum.

10. Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology.

11. Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection.

12. Development and Characterization of New Monoclonal Antibodies Against Porcine Interleukin-17A and Interferon-Gamma.

13. The Natural Cytotoxicity Receptor NKp44 (NCR2, CD336) Is Expressed on the Majority of Porcine NK Cells Ex Vivo Without Stimulation.

14. Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.

15. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis.

16. Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients.

17. Identification of a blockade epitope of human norovirus GII.17.

18. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.

19. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.

20. Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study.

21. Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes.

22. Pharmacokinetic profiles of a SARS-COV-2 neutralizing antibody BD-604 in cynomolgus monkeys.

23. Defining HPV-specific B cell responses in patients with head and neck cancer.

24. Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins.

25. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

26. Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.

27. Characterization and protective activity of monoclonal antibodies directed against Fe (3+) ABC transporter substrate-binding protein of Glaesserella parasuis.

28. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.

29. GroEL is an immunodominant surface-exposed antigen of Rickettsia typhi.

30. Novel neutralizing human monoclonal antibodies against tetanus neurotoxin.

31. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.

32. Clearing drug interferences in myeloma treatment using mass spectrometry.

33. Characterisation and application of recombinant FVIII-neutralising antibodies from haemophilia A inhibitor patients.

34. Dissection of the anti-Candida albicans mannan immune response using synthetic oligomannosides reveals unique properties of β-1,2 mannotriose protective epitopes.

35. Assessment of low volume sampling technologies: utility in nonclinical and clinical studies.

36. [Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression].

37. ARGX-117, a therapeutic complement inhibiting antibody targeting C2.

38. Whole blood stability evaluation of monoclonal antibody therapeutics using volumetric absorptive microsampling.

39. Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes.

40. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

41. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.

42. Evolution of antibody immunity to SARS-CoV-2.

43. Tetanus vaccine-induced human neutralizing antibodies provide full protection against neurotoxin challenge in mice.

44. Optimization and method validation for the quantitative analysis of a monoclonal antibody and its related fab fragment in human plasma after intravitreal administration, using LC-MS/MS.

45. Bioanalysis of therapeutic monoclonal antibody by peptide adsorption-controlled LC-MS.

46. Quantification of surrogate monoclonal antibodies in mouse serum using LC-MS/MS.

47. Monoclonal Antibody-Based Biosensor for Point-of-Care Detection of Type III Secretion System Expressing Pathogens.

48. Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies.

49. The Optimal Dose of Tacrolimus in Combination Therapy with an Anti-TNFα Antibody in a Mouse Colitis Model.

50. UNIVmAb reactive albumin associated hyaladherin as a potential biomarker for colorectal cancer.

Catalog

Books, media, physical & digital resources